| Literature DB >> 35570883 |
Noni Mumba1, Patricia Njuguna1,2, Primus Chi1, Vicki Marsh1,3, Esther Awuor1, Mainga Hamaluba1,3, Cynthia Mauncho1, Salim Mwalukore1, Johnson Masha1, Mary Mwangoma1, Betty Kalama1, Hassan Alphan1, Juliana Wambua1, Philip Bejon1,3, Dorcas Kamuya1,3, Melissa C Kapulu1,3.
Abstract
Human infection studies (HIS) involve deliberately infecting healthy volunteers with disease-causing pathogens under controlled conditions. These studies are "controlled" by way of using specific types of pathogens, including dose, and the availability of emergency medical facilities to research volunteers. Most HIS involve diseases whose treatment is known and are done to accelerate the development of novel therapeutics such as vaccines, to address emerging and existing infectious diseases. Traditionally, HIS have been conducted primarily in high-income countries (HICs) but are now increasingly being conducted in low-and-middle income countries (LMICs). In LMICs settings, HIS are likely to raise concerns among various stakeholders including participating populations and regulatory bodies, that are unfamiliar with this type of research. Deliberately infecting a healthy individual with a disease-causing pathogen seems to go against the normal practice of medicine of "do no harm". Such types of studies can give rise to increased rumors and jeopardize research participation in study activities, including non-HIS research. Community engagement can be one approach to address particular issues that HIS studies raise through meaningfully engaging with communities, where views and voices inform the conduct of HIS studies. In addition, engagement can inform the ethical conduct and acceptability of HIS studies in LMICs settings and provide opportunities for sharing information, listening to, and responding to concerns and views from potential participants, and the larger community in which the study would be conducted. Despite community engagement being an important aspect to consider, very few published and gray literature cover the types of approaches that have been used, and lessons learnt in engagement for HIS. This article outlinesthe community engagement approaches that were used to engage stakeholders and communities for malaria HIS-controlled human malaria infection (CHMI), undertaken in Kilifi, Kenya. It outlines the engagement activities across the research cycle, from activities conducted during protocol development, to planning, and implementation of the study. We discuss the challenges experienced, lessons learnt, and provide some recommendations for engagement around HIS.Entities:
Keywords: challenges and lessons; community engagement approaches; human infection studies; malaria; stakeholder identification
Mesh:
Year: 2022 PMID: 35570883 PMCID: PMC9099019 DOI: 10.3389/fpubh.2022.793913
Source DB: PubMed Journal: Front Public Health ISSN: 2296-2565
Figure 1Programme-wide and study-specific community engagement at KWTRP.
Figure 2Flow diagram depicting how engagement planning was done for the CHMI–SIKA study.
Key stakeholders identified by the CAST team for CHMI–SIKA in Kilifi and engagement approaches used.
|
|
|
|---|---|
| • | • |
| • | • |
| • | • |
| • | • |
| • | • |
| • | • |
| • | • |
| • | • |
Key messages derived by the CAST team for community engagement in the CHMI–SIKA study.
|
|
|---|
| • The question researchers wanted to answer with the study, and why it was important |
| • The study site(s), targeted study volunteers, and study procedures |
| • Risks/costs of study participation as well as potential benefits |
| • Safety issues in deliberately infecting healthy volunteers, certainty around the nature of what was being injected |
| • Health concerns over the possibility that treatment given eventually would fail to achieve a cure |
| • Safety issues in relation to the total volume of blood taken, given that sampling was to be frequent over a prolonged period of time |
| • Information around what would happen in the case of serious adverse events or death |
| • In-patient stay for around 25 days, and how volunteers would be compensated for their time away from employment/business. |
Common questions and concerns about CHMI–SIKA raised by community members, study volunteers, stakeholders and KWTRP staff who participated in engagement sessions.
| • What if the required 18–45 age bracket people who will consent become less than the required number, can an over age person be recruited? (Community members and study volunteers) |
| • What happens when one dies after being injected with the malaria parasite? (Community members and study volunteers) |
| • Will you cater for the families of those you will ‘admit’ because they won't be able to work for their families? (Community members and study volunteers) |
| • If I come for the screening and you find out that I have a [health] condition, will you treat me? (Study volunteers) |
| • While ‘admitted’ at [local] in-patient facility, will I be allowed to go home to [visit] my family and then come back, or not? (Community members and study volunteers) |
| • What happens if after admission [being challenged and treated] I fall sick again? (Study volunteers) |
| • What is the possibility of non-clearance of parasites with antimalarials at the end of the study and what could be the effects of that on me? (Community members and study volunteers) |
| • What if I am a heavy drinker of alcohol? (Community members) |
| • How do you get the parasites? From people or from the mosquitoes? (Community members) |
| • Relationships can be affected if one partner consents to participate in this study, and the other refutes their partner's participation. (Community members, study volunteers, KWTRP staff) |
| • Why does KEMRI take a lot of blood from participants (also linked to devil worship)? (Community members, study volunteers) |
| • There is no privacy and confidentiality at the study in-patient facility; drawing of blood is done openly (in view of other volunteers). (Study volunteers) |
In parenthesis included are examples of stakeholder groups that raised the question(s).